CFO of Horizon Discovery Group plc since 2012, leading one of the most successful ever Life Science IPOs on AIM raising £68.6m in a heavily oversubscribed IPO at the top of its valuation range, followed by two major US acquisitions within 6 months.
First class degree in Biological Sciences from Durham University and a qualified chartered accountant, advising numerous companies from lab bench to global pharma.
Previously Vice President, Finance at CSR plc, a FTSE 250 company with $1bn of revenues. Richard had worldwide responsibility for finance, with significant contributions to the $500m transformational acquisition and integration of NASDAQ listed Zoran Corp., product portfolio management, R&D financial management and business investment / divestment decisions.
Before this, Richard was a director in Deloitte’s life sciences practice, working with leading life science companies such as AstraZeneca, Vectura, Cambridge Antibody Technology and Abcam. He specialised in capital market transactions including numerous IPOs, M&As and fundraisings on AIM, Main Market and NASDAQ.
Beyond corporate responsibilities, Richard has advised the European Committee on funding for life science companies and is a regular presenter at investor conferences and technical seminars on financial issues facing the life science industry.